Dongkook Life Science Q1 2026: Slight Net Profit Increase, Market Share Growth Continues

Q1 2026 revenue: 33.1 billion KRW (down 5.6% YoY from 35.1 billion), operating profit 3.4 billion, net profit 2.3 billion (up 2.5% YoY from 2.2 billion)
Domestic revenue 31.1 billion (up 5.6% YoY) vs overseas revenue 2.0 billion (down 64.7% YoY)
Contrast media market share: 22.6% (2024), continuous increase
Dec 2024 regulatory action: 4-month suspension of API (Iopamidol) manufacturing (Jan-May 2025); sufficient inventory mitigates impact
R&D expense: 0.8 billion (2.4% of sales); ongoing facility investment (Ansung plant expansion)
Debt ratio 67.5%, current ratio 170.8%; stable financial structure
No shareholder return policy (no share buyback/dividend)